LIFECORE BIOMEDICAL, INC. Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent
LIFECORE BIOMEDICAL, INC. (LFCR) reported Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent of $5.23 million for the 3-month period ending 2016-08-28, per its 10-Q filed 2016-09-29.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent · last filed 2016-09-29
- LIFECORE BIOMEDICAL, INC. other comprehensive income (loss), before tax, portion attributable to parent for the quarter ending 2016-08-28 was $5.23M, a 11.86% increase year-over-year.
- LIFECORE BIOMEDICAL, INC. other comprehensive income (loss), before tax, portion attributable to parent for the quarter ending 2016-05-29 was $7.15M.
- LIFECORE BIOMEDICAL, INC. other comprehensive income (loss), before tax, portion attributable to parent for the quarter ending 2016-02-28 was -$33.68M, a 649.65% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. other comprehensive income (loss), before tax, portion attributable to parent for the quarter ending 2015-11-29 was $3.00M, a 40.44% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. other comprehensive income (loss), before tax, portion attributable to parent for fiscal 2016 was -$18.85M, a 187.80% decline from fiscal 2015.
- LIFECORE BIOMEDICAL, INC. other comprehensive income (loss), before tax, portion attributable to parent for fiscal 2015 was $21.47M, a 28.25% decline from fiscal 2014.
- LIFECORE BIOMEDICAL, INC. other comprehensive income (loss), before tax, portion attributable to parent for fiscal 2014 was $29.93M, a 7.25% decline from fiscal 2013.
- LIFECORE BIOMEDICAL, INC. other comprehensive income (loss), before tax, portion attributable to parent for fiscal 2013 was $32.26M.
| Period end | Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2016-08-28 | $5.23M 10-Q · filed 2016-09-29 | $12.38M derived: sum of 2 quarters · filed 2016-09-29 | -$21.29M derived: sum of 3 quarters · filed 2016-09-29 | -$18.30M derived: sum of 4 quarters · filed 2016-09-29 |
| 2016-05-29 | $7.15M derived: 10-K 12 month − 10-Q 9 month · filed 2016-08-01 | -$26.53M derived: sum of 2 quarters · filed 2016-08-01 | -$23.53M derived: sum of 3 quarters · filed 2016-08-01 | -$18.85M 10-K · filed 2016-08-01 |
| 2016-02-28 | -$33.68M 10-Q · filed 2016-03-30 | -$30.68M derived: sum of 2 quarters · filed 2016-03-30 | -$26.00M 10-Q · filed 2016-03-30 | |
| 2015-11-29 | $3.00M 10-Q · filed 2016-01-07 | $7.68M 10-Q · filed 2016-01-07 | ||
| 2015-08-30 | $4.68M 10-Q · filed 2016-09-29 | |||
| 2015-05-31 | $21.47M 10-K · filed 2016-08-01 | |||
| 2015-03-01 | $6.13M 10-Q · filed 2016-03-30 | $11.16M derived: sum of 2 quarters · filed 2016-03-30 | $14.88M 10-Q · filed 2016-03-30 | |
| 2014-11-30 | $5.03M 10-Q · filed 2016-01-07 | $8.76M 10-Q · filed 2016-01-07 | ||
| 2014-08-31 | $3.73M 10-Q · filed 2015-10-01 | |||
| 2014-05-25 | $29.93M 10-K · filed 2016-08-01 | |||
| 2013-05-26 | $32.26M 10-K · filed 2015-07-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |